NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, today announced that Progyny’s executives will participate in a fireside chat at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 5:00 P.M. Pacific Time / 8:00 P.M. Eastern Time. They will also participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference 2024 on Wednesday, May 29, 2024, at 1:00 P.M. Central Time / 2:00 P.M. Eastern Time.
A live audiocast and replay will be available from the Events and Presentations section of Progyny’s website at http://investors.progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a transformative fertility, family building and women’s health benefits solution, trusted by the nation’s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth by CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes’ Best Employers, Financial Times, Inc. 5000, Inc. Power Partners, and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.
For Further Information, Please Contact:
Investors:
James Hart
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Selena Yang
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$14.08 |
Daily Change: | 0.10 0.72 |
Daily Volume: | 49,398 |
Market Cap: | US$1.270B |
November 14, 2024 November 12, 2024 August 06, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB